Key result
Felodipine extended release did not alter digoxin pharmacokinetics, but the 10 mg plain tablet increased peak plasma digoxin concentrations by 11% (P<0.05) compared to placebo.
Why the study?
Does felodipine alter plasma digoxin levels and haemodynamics in patients with congestive heart failure?
RCT (n=14)
Double-blind
cross-over
Does felodipine alter plasma digoxin levels and haemodynamics in patients with congestive heart failure?
Effect estimate: 11% increase
p-value: p=<0.05
Felodipine extended-release does not significantly alter digoxin pharmacokinetics in heart failure patients, whereas the plain tablet formulation increases peak digoxin levels and alters systolic time intervals.
No takes yet. Share an insight, caveat, or question.
Supports safe felodipine ER co-administration with digoxin in HF without adjustment; confirms formulation-specific pharmacokinetic effects.
Kirch et al. (1989) conducted an RCT in congestive heart failure (n=14). Felodipine (extended release and plain tablet) vs. Placebo was evaluated on peak plasma concentrations of digoxin (11% increase, p=<0.05). Felodipine extended release did not alter digoxin pharmacokinetics, but the 10 mg plain tablet increased peak plasma digoxin concentrations by 11% (P<0.05) compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: